Oncology Perspective

 
 

  • Key Data in Non-Hodgkin Lymphoma From EHA 2023   Key data in non-Hodgkin lymphoma from EHA 2023 include evidence for omitting radiotherapy, findings of no benefit of IV over IT methotrexate in CNS prophylaxis, and two positive CAR T-cell studies.
  • Medscape Physician Assistant Career Satisfaction Report 2023 Most physician assistants (PAs) said that they are glad they chose this career and would do it again. But which issues still affect their job satisfaction?
  • Clinical Updates in Myelofibrosis From EHA 2023   Novel strategies in ruxolitinib-refractory patients, use of BET inhibitors plus JAK inhibitors to deepen response, and luspatercept to tackle anemia are covered in myelofibrosis updates from EHA 2023.
  • Highlights on Thrombosis and Hemostasis From EHA 2023   Thrombosis and hemostasis highlights from EHA 2023 identify VTE as a major complication in acute promyelocytic leukemia, biomarkers for VTE in lung cancer, and an investigational thrombosis inhibitor.
  • At ASCO, the Cancer Community Hyped the Wrong Trial Oncologist Bishal Gyawali, MD, PhD, highlights concerns surrounding which trials the oncology community is choosing to celebrate.
  • Infographic: Vacation Destinations to Recharge Your Batteries Physicians can find what they and their families need for much-deserved summer relaxation in this list of US destinations for all preferences and personalities.
  • Episode 2: Evolving Research in the Field of Chronic Myeloid Leukemia   Drs Michael J. Mauro and Ehab Atallah discuss current chronic myeloid leukemia research, where the US stands in comparison with the world, and the important work being conducted by the Cure CML Consortium.
  • Episode 1: Chronic Myeloid Leukemia Therapy and the Mark Cuban Effect   Drs Michael J. Mauro and Hagop Kantarjian discuss the cost of chronic myeloid leukemia therapy, long-term safety, adverse events, and the financial toxicity to the patient and the healthcare system.
  • Endocrine Therapy Plus Targeted Agents in MBC Endocrine therapy remains the mainstay of treatment in metastatic breast cancer. Dr Erica Mayer discusses adding targeted agents as clinicians strive to improve therapeutic options and efficacy.
  • Key Abstracts in Early Breast Cancer From ASCO 2023   Dr Harold Burstein highlights abstracts in early breast cancer from ASCO 2023, including the NATALEE trial of CDK4/6 inhibitor ribociclib and a meta-analysis on risk reduction with ovarian ablation.
  • Key Abstracts in Metastatic Breast Cancer From ASCO 2023   Dr Harold Burstein highlights abstracts in metastatic breast cancer from ASCO 2023, including data on antibody-drug conjugates from the TROPiCS-02 trial update, and phase 2 data on the novel HER3-DXd.
  • Key Data in Endometrial Cancer From ASCO 2023   Top abstracts in endometrial cancer from ASCO 2023 include patient-reported outcomes in the RUBY trial, genetic testing referral rates, and the impact of MMR deficiency on immunotherapy responses.
  • Highlights in Renal Cell Carcinoma From ASCO 2023   Data on combination therapies, real-world findings on TKIs, and 4-year follow-up of the CLEAR study are among the highlights in renal cell carcinoma from ASCO 2023, as reported by Dr Eric Jonasch.
  • Key Data on Advanced NSCLC From ASCO 2023   Data from KEYNOTE-789, plus results on the EGFR exon 20 inhibitor sunvozertinib and a promising sotorasib combination for KRAS G12C-mutant disease, are highlights in advanced NSCLC from ASCO 2023.
  • Episode 4: Psychosocial and Psychological Adjustment in Cancer Survivorship   Drs Ann H. Partridge and Donald L. Rosenstein discuss psychosocial and psychological adjustments to a cancer diagnosis, treatment, and living with and beyond cancer in survivorship, including anxiety, grief, and suicidal ideation.
  • Death Is Not the Enemy Humans seem all too willing to embrace the harmful behaviors that can bring on premature death, the real foe.
  • Practice-Changing Data in Ovarian Cancer From ASCO 2023   Practice-changing data in platinum-resistant ovarian cancer, a novel triplet in unmutated disease, and long-term data on HIPEC are among highlights from ASCO 2023, chosen by Dr Susana Banerjee.
  • Clinical Advances in Multiple Myeloma From ASCO 2023   Improved outcomes using novel strategies and combination therapies in relapsed and severe disease highlight the multiple myeloma advances from ASCO 2023 chosen by Dr Jonathan Kaufman.
  • 25 Great Summer Vacations for Physicians: 2023 Summer is here, so check out these intriguing destinations to spark up your off-duty time.
  • DDW 2023: Common GI Conditions in Primary Care   Vivek Kaul, MD, discusses papers from Digestive Disease Week 2023 that have a major impact on common GI conditions seen in primary care.